NCT04043598 Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage
| NCT ID | NCT04043598 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Subarachnoid Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 320 participants |
| Start Date | 2022-05-24 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 320 participants in total. It began in 2022-05-24 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.
Eligibility Criteria
Inclusion Criteria: All adult patients suffering from non-traumatic subarachnoid haemorrhage. Exclusion Criteria: * Patients with major intra-cranial trauma * Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography * More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI) * Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation) * Declining of informed consent
Contact & Investigator
Anna S Messmer, MD
PRINCIPAL INVESTIGATOR
Department of Intensive Care, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Frequently Asked Questions
Who can join the NCT04043598 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Subarachnoid Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04043598 currently recruiting?
Yes, NCT04043598 is actively recruiting participants. Contact the research team at anna.messmer@insel.ch for enrollment information.
Where is the NCT04043598 trial being conducted?
This trial is being conducted at Sankt Gallen, Switzerland, Bern, Switzerland, Geneva, Switzerland.
Who is sponsoring the NCT04043598 clinical trial?
NCT04043598 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Anna S Messmer, MD at Department of Intensive Care, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland. The trial plans to enroll 320 participants.